{"filing":{"accession_number":"0001213900-26-080414","cik":"0001728328","ticker":"INM","company_name":"InMed Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298644-8k425_inmed.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026080414/ea0298644-8k425_inmed.htm"},"events":[{"id":19585,"run_id":17619,"accession_number":"0001213900-26-080414","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.94,"summary":"InMed Pharmaceuticals is merging with Mentari Therapeutics in a transaction involving a two-step merger structure. The transaction includes a $200 million pre-closing private placement and a concurrent $290 million private placement, with the combined company to operate under the Mentari Therapeutics name and trade on Nasdaq Capital Market under a new ticker symbol. Post-closing, Mentari shareholders will own approximately 98.85% and InMed shareholders approximately 1.15% of the combined entity.","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18711,"accession_number":"0001213900-26-080414","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a $200 million private placement by Mentari Therapeutics that is explicitly stated to close \"immediately prior to the completion of Mentari's merger with InMed Pharmaceuticals, Inc.\" and \"concurrently with the previously announced $290 million private placement.\" The press release emphasizes that \"The combined company will continue to operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market under a new ticker symbol,\" indicating this is part of a material merger transaction. While Item 7.01 is used for the disclosure, the substance centers on the merger activity and related financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:29:45.660879+00:00","company_name":"","ticker":null,"filing_date":""},{"id":18712,"accession_number":"0001213900-26-080414","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 discloses an amendment to the Securities Purchase Agreement for a $200 million pre-closing financing in connection with InMed's merger with Mentari Therapeutics. The filing describes the merger structure (two-step merger with Merger Subs), the amendment adding $200 million in additional securities, and the pro forma ownership structure post-closing (98.85% Mentari, 1.15% InMed shareholders). This is material M\u0026A activity—specifically the financing component of a merger transaction that materially affects the deal structure and valuation framework.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:29:45.660879+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18711,"accession_number":"0001213900-26-080414","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a $200 million private placement by Mentari Therapeutics that is explicitly stated to close \"immediately prior to the completion of Mentari's merger with InMed Pharmaceuticals, Inc.\" and \"concurrently with the previously announced $290 million private placement.\" The press release emphasizes that \"The combined company will continue to operate under the Mentari Therapeutics name and trade on the Nasdaq Capital Market under a new ticker symbol,\" indicating this is part of a material merger transaction. While Item 7.01 is used for the disclosure, the substance centers on the merger activity and related financing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:29:45.660879+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-22"},{"id":18712,"accession_number":"0001213900-26-080414","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"This Item 8.01 discloses an amendment to the Securities Purchase Agreement for a $200 million pre-closing financing in connection with InMed's merger with Mentari Therapeutics. The filing describes the merger structure (two-step merger with Merger Subs), the amendment adding $200 million in additional securities, and the pro forma ownership structure post-closing (98.85% Mentari, 1.15% InMed shareholders). This is material M\u0026A activity—specifically the financing component of a merger transaction that materially affects the deal structure and valuation framework.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:29:45.660879+00:00","company_name":"InMed Pharmaceuticals Inc.","ticker":"INM","filing_date":"2026-07-22"}]}